Literature DB >> 12092455

The genetics of autoimmune polyendocrine syndrome type II.

David T Robles1, Pamela R Fain, Peter A Gottlieb, George S Eisenbarth.   

Abstract

A series of autoimmune disorders, often Addison's disease, type 1 diabetes mellitus, and thyroid autoimmunity, frequently occurs together in patients with the autoimmune polyendocrine syndrome type II (APS-II). The highest risk HLA genotype for Addison's disease, either as a single disease or in APS-II patients, consists of the genotype DR3/4, DQ2/DQ8 with DRB1*0404. As many as 30% of patients with Addison's disease have this genotype versus less than 0.5% of controls. An additional and important associated locus within the HLA region is the class I related gene, MIC-A. Patients who develop Addison's disease often have a delayed diagnosis and may die from Addisonian crisis; therefore, improved genetic testing combined with testing for 21-hydroxylase autoantibodies might allow the identification of relatively high-risk populations (greater than 1 in 200 defined genetic risk compared with 1 in 10,000 population risk).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12092455     DOI: 10.1016/s0889-8529(01)00015-9

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  4 in total

Review 1.  Polyglandular autoimmune syndromes.

Authors:  G J Kahaly; L Frommer
Journal:  J Endocrinol Invest       Date:  2017-08-17       Impact factor: 4.256

2.  A Case of Autoimmune Polyglandular Syndrome (APS) Type II with Hypothyroidism, Hypoadrenalism, and Celiac Disease - A Rare Combination.

Authors:  Manoj Lakhotia; Hans Raj Pahadia; Harish Kumar; Jagdish Singh; Sandeep Tak
Journal:  J Clin Diagn Res       Date:  2015-04-01

3.  Immunogenetics of Hashimoto's thyroiditis.

Authors:  Dimitry A Chistiakov
Journal:  J Autoimmune Dis       Date:  2005-03-11

Review 4.  Autoimmune Addison's Disease as Part of the Autoimmune Polyglandular Syndrome Type 1: Historical Overview and Current Evidence.

Authors:  Roberto Perniola; Alessandra Fierabracci; Alberto Falorni
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.